Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

Maio, Ermelinda De; Gravina, Adriano; Pacilio, Carmen; Amabile, Gerardo; Labonia, V.; Landi, G.; Nuzzo, Francesco; Rossi, Emanuela; D’Aiuto, Giuseppe; Capasso, Immacolata; Rinaldo, Massimo; Morrica, Brunello; Elmo, M.; Maïo, Massimo Di; Perrone, Francesco; Matteis, A. De

doi:10.1186/1471-2407-5-30

Cited by 33 publications

(21 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The IBCSG [81] examined the toxicity encountered in the elderly subgroup of patients treated with three cycles of classic CMF planned at full doses and found a significant relationship between older age and increased incidence of grade 3 toxicity from adjuvant chemotherapy, with no significant difference in survival between the treatment groups. Similar findings of a relevant burden of toxicity with six cycles of CMF, were recently reported by another group in a single institution [82] suggesting that less toxic treatments should be studied for elderly patients.…”

Section: Chemotherapysupporting

confidence: 87%

Treatment of breast cancer in older women

et al. 2008

View full text Add to dashboard Cite

Section: Chemotherapysupporting

confidence: 87%

Treatment of breast cancer in older women

et al. 2008

View full text Add to dashboard Cite

“…Adverse events during goserelin plus letrozole treatment were assessed according to the National Cancer Institute Common Toxicity Criteria [11].…”

Section: Toxicity Evaluationmentioning

confidence: 99%

Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer

Yao

et al. 2011

Endocr J

View full text Add to dashboard Cite

“…The beneficial effects of chemotherapeutic agents can only be realised if patients comply with their use. Compared with the developed countries, patients' compliance with chemotherapy in developing countries has been shown to be poorer [14][15][16][17].…”

Section: Introductionmentioning

confidence: 99%

Evaluation of patients\' adherence to chemotherapy for breast cancer

Adisa¹,

Lawal²,

Adesunkanmi³

2008

African Journal of Health Sciences

View full text Add to dashboard Cite

SUMMARYThe study aimed to establish the common reasons for non-adherence to drug treatment among breast cancer patients at the Obafemi Awolowo University Teaching Hospitals Complex, Ile-Ife, Nigeria over a ten-year period (Jan 1993 -Dec 2002). Patients' adherence and reasons for non-adherence to chemotherapy were evaluated using descriptive statistics. Two hundred and twenty-five breast cancer patients including 199 females and 6 males with breast cancer were recruited. 12(5.3%) patients had Stage I disease while 126 (56%) were in stage IV. The non-adherence rate was 80.9% and 111(73%) of the non-adherent patients were eventually not seen again. Of the one hundred and one patients who gave reasons for non-adherence, 45% complained of financial difficulties; 18% thought they were well enough; 15% were fearful of subsequent operation and 11% were unable to further bear the drug side effects. In conclusion, the study demonstrated poor economic status of the patients as one of the major reasons for non-adherence to cancer chemotherapy in Nigeria. Government subsidy of breast cancer treatment, improved health education and advocacy complemented by home visiting to encourage hospital attendance would be required for better adherence to chemotherapy.

show abstract

Compliance and toxicity of adjuvant CMF in elderly breast cancer patients: a single-center experience

Abstract: Background: Few data are available on compliance and safety of adjuvant chemotherapy when indicated in elderly breast cancer patients; CMF (cyclophosphamide, methotrexate, fluorouracil) can be reasonably considered the most widely accepted standard of treatment.

Cited by 33 publications

References 26 publications

Treatment of breast cancer in older women

Treatment of breast cancer in older women

Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer

Evaluation of patients\' adherence to chemotherapy for breast cancer

Contact Info

Product

Resources

About